Individual results vary based on each patients health history, laboratory findings, and clinical presentation
What they found: Oral AOD-9604 reduced body fat by 18 to 22 % vs placebo, comparable to injection administration No changes in total body weight (because lean mass rose slightly) Decrease in plasma triglycerides by 30 % Decrease in resting free fatty acids (paradoxically, mobilization of fat from depots into oxidation) No GI side effects Why it matters: It suggested that AOD-9604 could work orally , a rare property for a peptide
BPC 157 promotes gastrointestinal tract healing and protects against lesions, maintaining the integrity of the stomach lining and other tissues
Medical Faculty J.J
The peptide interacts with the nitric oxide (NO) system, modulating vascular tone and cell signaling at the microenvironmental level to support the transition from the inflammatory phase to the proliferative phase of healing
BPC-157 Research Relevant to Wolverine Stack Claims BPC-157 has a larger preclinical publication record than TB-500, but most musculoskeletal evidence remains non-human